Veru advances enobosarm obesity program with FDA clarity, raises $23M despite capital constraints

Filed May 13, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 8, 2025 · ~2 min read

Key Changes

• high

  FDA confirmed incremental weight loss ≥5% over GLP-1 therapy alone is an acceptable approval endpoint, or <5% with physical function benefit could support approval—providing clear regulatory path and quantitative efficacy thresholds for Phase 3.

  MD&A: FDA Regulatory Guidance verify on EDGAR →
• high

  Phase 2b QUALITY study showed enobosarm had favorable safety profile with no liver toxicity, no masculinization, no suicidal ideation, and actually reduced GI side effects versus semaglutide alone; maintenance extension demonstrated 46% reduction in weight regain after stopping GLP-1 therapy.

  MD&A: QUALITY Study Results verify on EDGAR →
• high

  Company raised $23.4M in October 2025 equity offering but remains subject to going concern disclosure; new SEC 'baby shelf' rule limits future capital raises to ~$12.8M annually (one-third of $38.5M public float), potentially forcing operational cutbacks if float declines further.

  MD&A: Equity Offering / Risk Factors: Baby Shelf Rule verify on EDGAR →